WntResearch recently announced that the Spanish authorities have approved the revised study plan for the phase II study NeoFox with the drug candidate Foxy-5 in colon cancer. The company has introduced new endpoints on the primary tumour already at the patients' surgery, which enables significantly earlier data readout and thus cost and time savings.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
11.9 SEK | +0.42% |
|
+10.70% | +29.35% |
03/05 | WntResearch AB Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
29/02 | WntResearch AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 | CI |
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+29.35% | 98L | |
+16.45% | 12TCr | |
+19.15% | 11TCr | |
+2.62% | 2.27TCr | |
-16.26% | 2.13TCr | |
-39.57% | 1.69TCr | |
-13.99% | 1.67TCr | |
-16.29% | 1.66TCr | |
+3.15% | 1.36TCr | |
+21.93% | 1.1TCr |
- Stock Market
- Equities
- WNT Stock
- News WntResearch AB
- WntResearch AB Announces New Study Plan Approves for Wnt Research's Phase II Study